Ilia Bernstein, MD
Endocrinology, Diabetes & Metabolism · Charleston, WVNPI 1881049146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $649, 2.2 times the $295 reported in 2022.
Across 25 payments — averaging $63.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$381
- Dexcom, Inc.$378
- Novo Nordisk$272
- Medtronic$160
- Sanofi-aventis U.S. LLC$149
- Amgen$125
- plus $135 from 2 others
What the payments were for
- Food & beverage$1,600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $381 |
| Dexcom, Inc. | 4 | $378 |
| Novo Nordisk | 9 | $272 |
| Medtronic | 3 | $160 |
| Sanofi-aventis U.S. LLC | 2 | $149 |
| Amgen | 1 | $125 |
| Nevro Corp. | 1 | $95 |
| Insulet Corporation | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$161
- DEXCOM STELO GLUCOSE BIOSENSOR$161
- Prolia$125
- ZEPBOUND$125
- Ozempic$125
- MOUNJARO$120
- MINIMED 780G$112
- DEXCOM G6 TRANSMITTER$100
How this compares
$1,600 in reported general payments places this provider in the 55th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 137 | $161,843 |
| OzempicSemaglutide | 142 | $148,046 |
| MounjaroTirzepatide | 24 | $37,821 |
| TradjentaLinagliptin | 22 | $30,366 |
| JardianceEmpagliflozin | 18 | $26,961 |
| Gvoke Hypopen 2-PackGlucagon | 32 | $22,227 |
| JanuviaSitagliptin Phosphate | 16 | $15,207 |
| Novolog FlexpenInsulin Aspart | 59 | $13,508 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $11,850 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,796 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $11,548 |
| Gvoke Hypopen 1-PackGlucagon | 33 | $11,413 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,303 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $7,901 |
| SynthroidLevothyroxine Sodium | 66 | $4,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $381 | $199,664161 claims |
| Novo NordiskOzempic | $272 | $148,046142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Charleston
- Samar SankariCharleston$8K
- Brian AprillCharleston$6K
- Lee Ann SkaffCharleston$2K
- Nicholas CassisCharleston$2K
- Steven ArtzCharleston$1K
- Raghda SahloulCharleston$558
- Glenn CrottyCharleston$422
- Stephen GrubbCharleston$198
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.